Atara Biotherapeutics, Inc. (Nasdaq: ATRA) has granted 2,200 restricted stock units of its common stock to a newly hired employee. Approved by the Compensation Committee of Atara’s Board of Directors, this grant was made under the Atara Biotherapeutics, Inc. 2018 Inducement Plan on July 1, 2024. The grant is considered an inducement material to the employee’s acceptance of employment at Atara, following Nasdaq Listing Rule 5635(c)(4).
These restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date, and the remaining vesting in approximately equal quarterly installments over the subsequent three years, contingent upon the employee’s continuous employment with Atara.
Atara is disclosing this grant in accordance with Nasdaq Listing Rule 5635(c)(4).
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc., headquartered in Southern California, pioneers T-cell immunotherapy utilizing its novel allogeneic Epstein-Barr virus (EBV) T-cell platform. This approach aims to develop transformative therapies for cancer and autoimmune diseases, offering off-the-shelf cell therapies that can be rapidly administered from inventory. Atara’s innovative T-cell platform targets EBV, addressing the root cause of specific diseases, and includes next-generation AlloCAR-Ts for potential treatment across a wide spectrum of hematological malignancies and B-cell driven autoimmune conditions.”
